Sergiusz Nawrocki
University of Warmia and Mazury in Olsztyn · 139 works · 1,274 citations · h-index 16
Top works
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma
- START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.
- Zalecenia ogólne dotyczące postępowania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych układu pokarmowego (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)
- Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment: Results of a Randomized Phase II Study
- Students’ Knowledge about Cervical Cancer Prevention in Poland
- Genetically modified tumour vaccines – where we are today
- Numerical simulations for tumor and cellular immune system interactions in lung cancer treatment
- COVID-19 Pandemic: Impact on Cancer Patients
- LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
- From microarrays to new therapeutic approaches in bladder cancer
- How Long Are Cancer Patients Waiting for Oncological Therapy in Poland?
- Flow cytometric cytotoxicity assay with GFP gene modified target cells
- Pharmacotherapy of bladder cancer – practice and prospects
- Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study
- Genetically modified tumour vaccines (GMTV) in melanoma clinical trials
- Clinical study and numerical simulation of brain cancer dynamics under radiotherapy
- Complementary and Alternative Medicine Use in Hospitalized Cancer Patients—Study from Silesia, Poland
- Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer
- Evaluation of an electronic portal imaging device (target view, ge) as a quality assurance tool